- Home
- ATAT vs AMLX Comparison
ATAT vs AMLX Comparison
Compare ATAT & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATAT | AMLX |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.8B |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ATAT | AMLX |
|---|---|---|
| Price | $32.84 | $29.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $49.00 | $21.56 |
| AVG Volume (30 Days) | 667.1K | ★ 1.4M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.06% | N/A |
| EPS Growth | N/A | ★ 65.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $380,786,000.00 |
| Revenue This Year | $25.48 | N/A |
| Revenue Next Year | $18.11 | N/A |
| P/E Ratio | $26.11 | ★ N/A |
| Revenue Growth | N/A | ★ 1612.94 |
| 52 Week Low | $30.78 | $10.83 |
| 52 Week High | $43.17 | $41.14 |
Technical Indicators
Market Signals| Indicator | ATAT | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 47.17 | 42.72 |
| Support Level | $31.00 | $12.97 |
| Resistance Level | $33.41 | $34.35 |
| Average True Range (ATR) | 0.84 | 1.49 |
| MACD | 0.04 | -0.80 |
| Stochastic Oscillator | 69.35 | 13.84 |
Price Performance
Historical ComparisonAbout ATAT Atour Lifestyle Holdings Limited
Atour Lifestyle Holdings Ltd is an upper-midscale hotel chain in China. The company derives revenues from franchise and management fees from its manachised hotels and sales of hotel supplies to manachised hotels, Operations of leased hotels, and sales of retail products. The company has one operating segment, which is the Atour Group.
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.